Intellia Therapeutics, Inc.

LSE:0JBU Stock Report

Market Cap: US$1.2b

Intellia Therapeutics Management

Management criteria checks 2/4

Intellia Therapeutics' CEO is John Leonard, appointed in Jan 2018, has a tenure of 6.92 years. total yearly compensation is $11.66M, comprised of 5.7% salary and 94.3% bonuses, including company stock and options. directly owns 0.82% of the company’s shares, worth $9.94M. The average tenure of the management team and the board of directors is 6.3 years and 9.7 years respectively.

Key information

John Leonard

Chief executive officer

US$11.7m

Total compensation

CEO salary percentage5.7%
CEO tenure6.9yrs
CEO ownership0.8%
Management average tenure6.3yrs
Board average tenure9.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Leonard's remuneration changed compared to Intellia Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$522m

Jun 30 2024n/an/a

-US$509m

Mar 31 2024n/an/a

-US$486m

Dec 31 2023US$12mUS$660k

-US$481m

Sep 30 2023n/an/a

-US$462m

Jun 30 2023n/an/a

-US$453m

Mar 31 2023n/an/a

-US$430m

Dec 31 2022US$10mUS$630k

-US$474m

Sep 30 2022n/an/a

-US$442m

Jun 30 2022n/an/a

-US$400m

Mar 31 2022n/an/a

-US$369m

Dec 31 2021US$10mUS$600k

-US$268m

Sep 30 2021n/an/a

-US$229m

Jun 30 2021n/an/a

-US$185m

Mar 31 2021n/an/a

-US$149m

Dec 31 2020US$4mUS$580k

-US$134m

Sep 30 2020n/an/a

-US$120m

Jun 30 2020n/an/a

-US$116m

Mar 31 2020n/an/a

-US$109m

Dec 31 2019US$904kUS$559k

-US$100m

Sep 30 2019n/an/a

-US$90m

Jun 30 2019n/an/a

-US$89m

Mar 31 2019n/an/a

-US$86m

Dec 31 2018US$10mUS$550k

-US$85m

Sep 30 2018n/an/a

-US$90m

Jun 30 2018n/an/a

-US$83m

Mar 31 2018n/an/a

-US$76m

Dec 31 2017US$3mUS$396k

-US$68m

Compensation vs Market: John's total compensation ($USD11.66M) is above average for companies of similar size in the UK market ($USD2.42M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Leonard (67 yo)

6.9yrs

Tenure

US$11,657,262

Compensation

Dr. John M. Leonard, M. D. is an Executive Partner at Tyree & D'Angelo Partners. He serves as Director at 3T Biosciences, Inc. since October 2022. He has been Independent Director at IQVIA Holdings Inc. si...

Leadership Team

NamePositionTenureCompensationOwnership
John Leonard
President6.9yrsUS$11.66m0.82%
$ 9.9m
Laura Sepp-Lorenzino
Executive VP & Chief Scientific Officer5.6yrsUS$4.19m0.019%
$ 231.8k
James Basta
Executive VP3.5yrsUS$3.99m0.017%
$ 212.4k
David Lebwohl
Executive VP & Chief Medical Officer4.7yrsUS$4.26m0.029%
$ 350.9k
Nessan Bermingham
Founder & Member of Scientific Advisor Board10.6yrsUS$11.27mno data
Rachel Haurwitz
Co-Founder10.6yrsUS$311.57kno data
Andrew May
Founder and Member of Scientific Advisor Boardno datano datano data
Jennifer Doudna
Founder & Member of Scientific Advisor Boardno datano datano data
Derrick Rossi
Founder & Member of Scientific Advisor Boardno datano datano data
Rodolphe Barrangou
Founder & Member of Scientific Advisor Boardno datano datano data
Luciano Marraffini
Founder & Member of Scientific Advisor Boardno datano datano data
Erik Sontheimer
Founder & Member of Scientific Advisor Boardno datano datano data

6.3yrs

Average Tenure

60yo

Average Age

Experienced Management: 0JBU's management team is seasoned and experienced (6.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Leonard
President10.4yrsUS$11.66m0.82%
$ 9.9m
Nessan Bermingham
Founder & Member of Scientific Advisor Boardno dataUS$11.27mno data
Andrew May
Founder and Member of Scientific Advisor Boardno datano datano data
Jennifer Doudna
Founder & Member of Scientific Advisor Board9.7yrsno datano data
Derrick Rossi
Founder & Member of Scientific Advisor Board9.7yrsno datano data
Rodolphe Barrangou
Founder & Member of Scientific Advisor Boardno datano datano data
Luciano Marraffini
Founder & Member of Scientific Advisor Boardno datano datano data
Erik Sontheimer
Founder & Member of Scientific Advisor Boardno datano datano data
Arthur Krieg
Member of Scientific Advisory Boardno datano datano data
Beverly Davidson
Member of Scientific Advisory Board9.9yrsno datano data
Franciscus A. G. Verwiel
Independent Chairman of the Board7.4yrsUS$499.94k0.010%
$ 122.3k
William Chase
Independent Director1.7yrsUS$996.21k0.0067%
$ 81.4k

9.7yrs

Average Tenure

61yo

Average Age

Experienced Board: 0JBU's board of directors are considered experienced (9.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 16:02
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Intellia Therapeutics, Inc. is covered by 44 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jack AllenBaird
Huidong WangBarclays